Tasly Pharmaceutical Group Co., Ltd (SHA:600535)
China
· Delayed Price · Currency is CNY 15.19
+0.08 (0.53%)
Apr 29, 2026, 3:00 PM CST
SHA:600535 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Market Capitalization | 22,693 | 22,514 | 21,603 | 25,427 | 15,988 | 23,778 | Upgrade
|
| Market Cap Growth | 0.53% | 4.22% | -15.04% | 59.04% | -32.76% | 6.62% | Upgrade
|
| Enterprise Value | 21,518 | 20,078 | 19,116 | 24,806 | 15,103 | 23,396 | Upgrade
|
| Last Close Price | 15.19 | 15.07 | 14.08 | 15.84 | 9.80 | 13.98 | Upgrade
|
| PE Ratio | 19.55 | 20.38 | 22.61 | 23.74 | - | 10.08 | Upgrade
|
| Forward PE | 13.44 | 12.94 | 15.72 | 7.47 | 4.03 | 8.30 | Upgrade
|
| PS Ratio | 2.72 | 2.73 | 2.54 | 2.93 | 1.85 | 2.99 | Upgrade
|
| PB Ratio | 1.76 | 1.79 | 1.78 | 2.00 | 1.26 | 1.79 | Upgrade
|
| P/TBV Ratio | 1.89 | 1.94 | 1.91 | 2.16 | 1.34 | 1.93 | Upgrade
|
| P/FCF Ratio | 11.47 | 21.58 | 14.90 | 13.34 | 8.53 | 10.67 | Upgrade
|
| P/OCF Ratio | 10.08 | 15.80 | 10.72 | 9.87 | 7.01 | 8.49 | Upgrade
|
| PEG Ratio | - | 1.80 | 1.80 | 1.80 | 1.80 | 1.80 | Upgrade
|
| EV/Sales Ratio | 2.58 | 2.44 | 2.25 | 2.86 | 1.75 | 2.94 | Upgrade
|
| EV/EBITDA Ratio | 11.33 | 11.48 | 9.89 | 12.75 | 8.51 | 14.20 | Upgrade
|
| EV/EBIT Ratio | 14.51 | 14.60 | 13.30 | 17.22 | 11.27 | 18.83 | Upgrade
|
| EV/FCF Ratio | 10.88 | 19.24 | 13.19 | 13.01 | 8.05 | 10.49 | Upgrade
|
| Debt / Equity Ratio | 0.09 | 0.12 | 0.14 | 0.22 | 0.17 | 0.13 | Upgrade
|
| Debt / EBITDA Ratio | 0.61 | 0.79 | 0.86 | 1.46 | 1.17 | 0.98 | Upgrade
|
| Debt / FCF Ratio | 0.58 | 1.38 | 1.14 | 1.49 | 1.16 | 0.76 | Upgrade
|
| Net Debt / Equity Ratio | -0.10 | -0.22 | -0.15 | -0.15 | -0.16 | -0.16 | Upgrade
|
| Net Debt / EBITDA Ratio | -0.72 | -1.60 | -0.96 | -0.99 | -1.16 | -1.27 | Upgrade
|
| Net Debt / FCF Ratio | -0.66 | -2.68 | -1.28 | -1.01 | -1.10 | -0.94 | Upgrade
|
| Asset Turnover | 0.54 | 0.54 | 0.54 | 0.52 | 0.52 | 0.48 | Upgrade
|
| Inventory Turnover | 1.75 | 1.75 | 1.62 | 1.76 | 2.04 | 1.85 | Upgrade
|
| Quick Ratio | 2.22 | 2.90 | 2.34 | 2.91 | 3.54 | 4.10 | Upgrade
|
| Current Ratio | 3.72 | 3.57 | 3.11 | 3.69 | 4.31 | 4.99 | Upgrade
|
| Return on Equity (ROE) | 8.73% | 8.61% | 6.93% | 8.02% | -2.68% | 18.74% | Upgrade
|
| Return on Assets (ROA) | 6.04% | 5.67% | 5.67% | 5.43% | 5.08% | 4.70% | Upgrade
|
| Return on Invested Capital (ROIC) | 10.86% | 10.85% | 10.99% | 11.22% | 12.28% | 9.04% | Upgrade
|
| Return on Capital Employed (ROCE) | 11.10% | 10.60% | 11.40% | 10.00% | 9.40% | 8.50% | Upgrade
|
| Earnings Yield | 5.12% | 4.91% | 4.42% | 4.21% | -1.65% | 9.92% | Upgrade
|
| FCF Yield | 8.72% | 4.63% | 6.71% | 7.50% | 11.73% | 9.38% | Upgrade
|
| Dividend Yield | 2.05% | 2.06% | 3.76% | 2.08% | 3.37% | 2.36% | Upgrade
|
| Payout Ratio | 28.19% | 57.26% | 109.09% | 52.59% | - | 25.88% | Upgrade
|
| Buyback Yield / Dilution | -0.01% | - | -0.43% | -1.34% | 2.29% | -0.08% | Upgrade
|
| Total Shareholder Return | 2.06% | 2.06% | 3.34% | 0.75% | 5.66% | 2.27% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.